Valuation: Protalix BioTherapeutics, Inc.

Market Cap 20Cr 18Cr 17Cr 15Cr 29Cr 1.94TCr 29Cr 202.53Cr 80Cr 1.01TCr 77Cr 75Cr 3.22TCr P/E 2026 *
10.5x
P/E 2027 * 50.6x
Enterprise Value 20Cr 18Cr 17Cr 15Cr 29Cr 1.94TCr 29Cr 202.53Cr 80Cr 1.01TCr 77Cr 75Cr 3.22TCr EV / Sales 2026 *
2.48x
EV / Sales 2027 * 3.07x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day+2.02%
1 week-4.17%
Current month-8.33%
1 month-6.99%
3 months+5.42%
6 months+17.13%
Current year+40.56%
1 week 2.46
Extreme 2.46
2.6
1 month 2.46
Extreme 2.46
2.82
Current year 1.72
Extreme 1.72
3.19
1 year 1.65
Extreme 1.65
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 83 01/11/2014
Director/Board Member 59 30/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Free

Director

25,500 0.0316%
03/09/26 Free

Chairman

25,500 0.0316%
03/09/26 Free

Chief Executive Officer

4,80,000 0.5957%
Change 5-day change 1-year change 3-year change Capi.($)
+2.02%-4.17%+6.30%+76.92% 20Cr
+0.22%-0.14%+55.12%+128.82% 1,14000Cr
+0.91%+3.61%+41.21%+84.57% 64TCr
-0.12%-0.93%+25.59%+106.14% 51TCr
+0.63%+2.33%+49.21%+67.82% 38TCr
+0.86%-4.37%+61.16%+37.93% 35TCr
+1.02%+1.80%+24.84%+53.75% 29TCr
-0.25%+1.62%+2.20%+26.65% 27TCr
+0.75%+2.05%+53.85%+71.25% 24TCr
+0.25%+1.64%+32.05%+107.62% 20TCr
Average +0.63%+2.32%+35.15%+76.15% 40.14TCr
Weighted average by Cap. +0.44%+2.98%+42.20%+88.48%

Financials

2026 *2027 *
Net sales 8.22Cr 7.37Cr 6.81Cr 6.17Cr 12Cr 780.38Cr 12Cr 82Cr 32Cr 409.05Cr 31Cr 30Cr 1.3TCr 6.65Cr 5.97Cr 5.51Cr 5Cr 9.34Cr 631.46Cr 9.45Cr 66Cr 26Cr 330.99Cr 25Cr 24Cr 1.05TCr
Net income 1.96Cr 1.76Cr 1.63Cr 1.48Cr 2.76Cr 186.47Cr 2.79Cr 20Cr 7.75Cr 98Cr 7.37Cr 7.21Cr 309.96Cr 37.94L 34.05L 31.44L 28.51L 53.29L 36Cr 53.94L 3.77Cr 1.5Cr 19Cr 1.42Cr 1.39Cr 60Cr
Net Debt - -
Projected Income Statement - Annual - Protalix BioTherapeutics, Inc.
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
27/26/27 $2.530 +2.02% 4,48,302
26/26/26 $2.480 -2.75% 4,16,271
23/26/23 $2.550 -0.78% 3,83,908
22/26/22 $2.570 0.00% 4,57,114
21/26/21 $2.570 -2.65% 5,61,517
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Protalix BioTherapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.530USD
Average target price
11.00USD
Spread / Average Target
+334.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Protalix BioTherapeutics, Inc.